Over 173M lives covered with the addition of Anthem BlueCross BlueShield of Georgia, which covers approximately 3.3 million members across the state
For a pdf copy of this release please click here
AUSTIN, Texas — October 14, 2020 — Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that it has further expanded network access for both OVA1® and ASPIRA GenetiXSM Testing. Aspira is now a participating provider for all PAR/PPO and Medicare Advantage PPO products of Anthem BlueCross BlueShield of Georgia, an independent licensee of the Blue Cross Blue Shield Association.
“We are pleased that we are now a participating provider with BlueCross BlueShield of Georgia network,” said Valerie Palmieri, President and CEO of Aspira Women’s Health Inc. This is a considerable plan as it represents close to 30% of Georgia’s population. We can now provide more physicians and patients access to OVA1 and GenetiX, which will help ensure that women of ALL ages, stages, and ethnicities have the best solutions available to assess their personalized risk of ovarian cancer at the earliest stage when it matters most.”